Semaglutide
- Generic Name
- Semaglutide
- Brand Names
- Ozempic, Rybelsus, Wegovy
- Drug Type
- Small Molecule
- Chemical Formula
- C187H291N45O59
- CAS Number
- 910463-68-2
- Unique Ingredient Identifier
- 53AXN4NNHX
- Background
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. Other members of this drug class include Exenatide and Liraglutide. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. Th...
- Indication
Semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus, and is used as an adjunct to diet and exercise. However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not in...
- Associated Conditions
- BMI >27 kg/m2, Cardiovascular Events, Obesity, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 9642
- Registration Number
- NCT03914326
- Locations
- 🇦🇷
Centro de Investigaciones Metabólicas, Capital Federal, Argentina
🇦🇷Centro Diabetologico Cordoba Dr. Waitman, Cordoba, Argentina
🇦🇷Centro médico privado Cemaic, Córdoba, Argentina
Triple Therapy in T1DM
- Conditions
- Interventions
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- State University of New York at Buffalo
- Target Recruit Count
- 114
- Registration Number
- NCT03899402
- Locations
- 🇺🇸
Diabetes and Endocrinology Research Center of WNY, Williamsville, New York, United States
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- Conditions
- Interventions
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2024-10-24
- Target Recruit Count
- 84
- Registration Number
- NCT03884075
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 215
- Registration Number
- NCT03876015
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wellingborough, United Kingdom
A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 72
- Registration Number
- NCT03842202
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3508
- Registration Number
- NCT03819153
- Locations
- 🇺🇸
Alliance for Multispec Res, Norman, Oklahoma, United States
🇺🇸Juno Research, LLC_Houston, Houston, Texas, United States
🇺🇸Oceane 7 Medical & Research Center, Inc., Miami, Florida, United States
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1500
- Registration Number
- NCT03811561
- Locations
- 🇺🇸
Diabetes/Lipid Mgmt & Res Ctr, Huntington Beach, California, United States
🇸🇰Nemocnica akademika L. Derera, UNB, Bratislava, Slovakia
🇺🇸Del Sol Research Management, LLC, Tucson, Arizona, United States
STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity
- Conditions
- Interventions
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 401
- Registration Number
- NCT03811574
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Yangsan, Korea, Republic of
A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together
- Conditions
- Interventions
- First Posted Date
- 2018-12-28
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 30
- Registration Number
- NCT03789578
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese
- Conditions
- Interventions
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 88
- Registration Number
- NCT03707990
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Tempe, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.